The clinical response to anti-IL5/5R drugs mepolizumab and benralizumab appears to be the same in patients whether or not they have a severe allergic component to their asthma, research suggests. A team at Guy’s Severe Asthma Centre in London compared clinical outcomes with the monoclonal antibodies between patients who were also eligible for omalizumab because ...
Targeting the eosinophil key in severe allergic asthma, studies suggest
By Emma Wilkinson
22 Mar 2021